Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer
Public ClinicalTrials.gov record NCT05261490. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase Ⅰ/Ⅱ Study of TTI-622 in Combination With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Pegylated liposomal doxorubicin (PLD), a type of chemotherapy, is a standard treatment option for patients with platinum-resistant ovarian cancer. However, despite being consider a standard treatment option, the clinical benefit of chemotherapy alone for these patients is small. Historically, response rates for PLD monotherapy have only ranged from 12 to 35% with a high likelihood of recurrence within months after treatment initiation. Although bevacizumab (BEV), an anti-new-vascular growth monoclonal antibody has been approved by FDA to combine with standard chemotherapy (e.g., PLD) for platinum-resistant recurrent ovarian cancer, there are still many restrictions or contraindications preventing certain women from receiving bevacizumab's combination treatment. The goal of this study is to improve upon the activity of PLD in a safe manner to provide a more effective therapeutic option for this group of patients. The purpose of this study is to assess maplirpacept (PF-07901801) administered in combination with PLD in patients with platinum-resistant ovarian cancer and for whom PLD is a reasonable treatment option. The first portion of the study will evaluate the safety of increasing dose levels of maplirpacept (PF-07901801) in combination with PLD at 40 mg/m2 in patients with platinum-resistant EOC (epithelial ovarian cancer). This is a group of cancer, including ovarian, peritoneal, and fallopian tube malignancy. The aim of the first portion of the study is to establish a combination regimen for further assessment in a dose expansion cohort. The study will consist of a 28-day screening period to ensure participants are qualified for the study treatment plan. During the treatment period, patients will receive maplirpacept (PF-07901801) in combination with PLD in 28-day cycles until their disease progresses or unacceptable toxicity develops. There will be a long-term follow-up period in this study to assess overall survival (length of time since start of treatment patients are alive).
Study identification
- NCT ID
- NCT05261490
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 10 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 1, 2022 (Actual)
- Primary completion
- Oct 11, 2023 (Actual)
- Completion
- Feb 15, 2024 (Actual)
- Last update posted
- Nov 19, 2024
2022 – 2024
United States locations
- U.S. sites
- 18
- U.S. states
- 8
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sarcoma Oncology Research Center | Santa Monica | California | 90403 | — |
| Baptist Hospital of Miami | Miami | Florida | 33176 | — |
| Miami Cancer Institute at Baptist Health, Inc. | Miami | Florida | 33176 | — |
| Orlando Health Cancer Institute Gynecologic Cancer Center | Orlando | Florida | 32806 | — |
| Orlando Health Cancer Institute | Orlando | Florida | 32806 | — |
| Michigan Healthcare Professionals PC | Dearborn | Michigan | 48126 | — |
| Michigan Healthcare Professionals PC | Farmington Hills | Michigan | 48334 | — |
| Michigan Healthcare Professionals PC | Royal Oak | Michigan | 48073 | — |
| Michigan Healthcare Professionals PC | Sterling Heights | Michigan | 48314 | — |
| Cleveland Clinic taussig Cancer Center Investigational Pharmacy | Cleveland | Ohio | 44106 | — |
| Cleveland Clinic Fairview Hospital | Cleveland | Ohio | 44111 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Cleveland Clinic Hillcrest Hospital | Mayfield Heights | Ohio | 44124 | — |
| Oklahoma Cancer Specialist and Research Institute. LLC | Tulsa | Oklahoma | 74146 | — |
| Magee-Womens Hospital of UPMC | Pittsburgh | Pennsylvania | 15213 | — |
| UPMC Hillman Cancer Center-Investigational Drug Services | Pittsburgh | Pennsylvania | 15232 | — |
| Avera Cancer Institute | Sioux Falls | South Dakota | 57105 | — |
| oncology Consultants, P.A. | Houston | Texas | 77024 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05261490, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 19, 2024 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05261490 live on ClinicalTrials.gov.